WALTHAM, Mass. (Nov 03, 2009) IntrinsiQ, the company improving the quality and understanding of cancer care, today announced that Mike Raquet has been appointed as the company's first vice president of business development. Maria Rugani will take over Raquet's previous role as general manager of the pharmaceutical data division.
Each with 25 years experience in the pharmaceutical industry, Raquet and Rugani will shape the development of new data solution offerings and consulting services to bring together key constituents – across key roles within pharma organizations and enlisting patients, providers and payors – to develop safer and more efficacious oncology drugs, faster.
"As the medical oncology drug market becomes more and more specialized, the stakes get exponentially higher for research and development, clinical trials, and sales and marketing," said Jeff Forringer, IntrinsiQ president. "Add health reform pressures to this shifting market landscape, and pharmaceutical organizations are facing an unprecedented era of greater uncertainty and risk. They'll need rock-solid answers, faster, in bringing new oncology drugs to market. Mike and Maria will keep us one step ahead of their questions."
IntrinsiQ is already considered oncology's leading source of real-time, real-world data for cancer treatment. Its analysis of over 1.6 million drug administrations from more than 600 oncologists collected annually through IntelliDose®, IntrinsiQ's flagship clinical software, helps everyone in the continuum of care identify the most effective treatments and emerging best practices.
A pharmaceutical industry veteran, Raquet brings first-hand experience of key pharma operations – including clinical research, drug marketing, sales and manufacturing from senior-level positions at IMS Health and PRA International. Under Raquet's guidance, IntrinsiQ will develop advisory boards of oncologists and pharmaceutical researchers to better understand and meet their evolving needs. The company is also developing new services for specific areas within pharmaceutical organizations including sales, clinical services, and competitive intelligence.
Rugani joined IntrinsiQ with its acquisition of WWMR, a leading primary research firm. She brings extensive experience in consulting and market research, specializing in cancer treatment and cancer supportive care. Earlier in her career, she was a client of IntrinsiQ, managing secondary data at a leading biotech oncology company. She has had direct responsibility for setting strategies for pricing, reimbursement, contracting, and managed care marketing functions.
Raquet and Rugani will report directly to Forringer.
IntrinsiQ, LLC is the leading provider of medical oncology clinical information systems and the premier source of US oncology data and analysis. Each month, IntrinsiQ's clinical software application, IntelliDose®, captures the treatment decisions and details from more than 600 oncologists, for nearly 20,000 unique patients, creating a database unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts. For more information, please visit www.intrinsiq.com.